2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice

Ilaria Pennacchia; Arnaldo Carbone; Arcangelo Di Cerbo; Fabio Maria Vecchio; Vincenzo Arena

doi:10.1016/j.breast.2015.01.014

2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice

Ilaria Pennacchia, Arnaldo Carbone, Arcangelo Di Cerbo, Fabio Maria Vecchio, Vincenzo Arena

Research output: Contribution to journal › Article

13 Citations (Scopus)

Abstract

The release of the new ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing has led to clearer descriptive definitions for immunohistochemistry categories. As soon as we started to use them we realized that an increase in the number of ISH test was occurring. Herein we report our lab data obtained by comparing the semester after the release of the new guidelines with the same semester of the previous year. The impact on routine work practice is highlighted.

Original language	English
Pages (from-to)	285-286
Number of pages	2
Journal	THE BREAST
Volume	24
DOIs	https://doi.org/10.1016/j.breast.2015.01.014
Publication status	Published - 2015

Keywords

ASCO/CAP
Breast Neoplasms
Early Detection of Cancer
Female
Guidelines
HER2
Humans
Neoplasm Proteins
Practice Guidelines as Topic
Practice Patterns, Physicians'
Receptor, ErbB-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.breast.2015.01.014

Cite this

@article{c3367b1f03404ba59348243b488e67df,

title = "2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice",

abstract = "The release of the new ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing has led to clearer descriptive definitions for immunohistochemistry categories. As soon as we started to use them we realized that an increase in the number of ISH test was occurring. Herein we report our lab data obtained by comparing the semester after the release of the new guidelines with the same semester of the previous year. The impact on routine work practice is highlighted.",

keywords = "ASCO/CAP, Breast Neoplasms, Early Detection of Cancer, Female, Guidelines, HER2, Humans, Neoplasm Proteins, Practice Guidelines as Topic, Practice Patterns, Physicians', Receptor, ErbB-2, ASCO/CAP, Breast Neoplasms, Early Detection of Cancer, Female, Guidelines, HER2, Humans, Neoplasm Proteins, Practice Guidelines as Topic, Practice Patterns, Physicians', Receptor, ErbB-2",

author = "Ilaria Pennacchia and Arnaldo Carbone and {Di Cerbo}, Arcangelo and Vecchio, {Fabio Maria} and Vincenzo Arena",

year = "2015",

doi = "10.1016/j.breast.2015.01.014",

language = "English",

volume = "24",

pages = "285--286",

journal = "THE BREAST",

issn = "0960-9776",

publisher = "Elsevier Science Limited:Oxford Fulfillment Center, PO Box 800, Kidlington Oxford OX5 1DX United Kingdom:011 44 1865 843000, 011 44 1865 843699, EMAIL: [email protected], [email protected], INTERNET: http://www.elsevier.com, http://www.elsevier.com/locate/shpsa/, Fax: 011 44 1865 843010",

}

TY - JOUR

T1 - 2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice

AU - Pennacchia, Ilaria

AU - Carbone, Arnaldo

AU - Di Cerbo, Arcangelo

AU - Vecchio, Fabio Maria

AU - Arena, Vincenzo

PY - 2015

Y1 - 2015

N2 - The release of the new ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing has led to clearer descriptive definitions for immunohistochemistry categories. As soon as we started to use them we realized that an increase in the number of ISH test was occurring. Herein we report our lab data obtained by comparing the semester after the release of the new guidelines with the same semester of the previous year. The impact on routine work practice is highlighted.

AB - The release of the new ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing has led to clearer descriptive definitions for immunohistochemistry categories. As soon as we started to use them we realized that an increase in the number of ISH test was occurring. Herein we report our lab data obtained by comparing the semester after the release of the new guidelines with the same semester of the previous year. The impact on routine work practice is highlighted.

KW - ASCO/CAP

KW - Breast Neoplasms

KW - Early Detection of Cancer

KW - Female

KW - Guidelines

KW - HER2

KW - Humans

KW - Neoplasm Proteins

KW - Practice Guidelines as Topic

KW - Practice Patterns, Physicians'

KW - Receptor, ErbB-2

KW - ASCO/CAP

KW - Breast Neoplasms

KW - Early Detection of Cancer

KW - Female

KW - Guidelines

KW - HER2

KW - Humans

KW - Neoplasm Proteins

KW - Practice Guidelines as Topic

KW - Practice Patterns, Physicians'

KW - Receptor, ErbB-2

UR - http://hdl.handle.net/10807/70981

U2 - 10.1016/j.breast.2015.01.014

DO - 10.1016/j.breast.2015.01.014

M3 - Article

SN - 0960-9776

VL - 24

SP - 285

EP - 286

JO - THE BREAST

JF - THE BREAST

ER -

2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this